Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Is Arcus Biosciences (RCUS) the dark horse of cancer immunotherapy after 26.7-month survival data?
Arcus stock jumped after its domvanalimab-zimberelimab combo showed 26.7-month survival in gastric cancer. Find out what this means for its TIGIT pipeline.
FDA doubles down on Palvella’s QTORIN rapamycin as Phase 3 SELVA trial exceeds enrollment
Find out how the FDA’s renewed orphan grant is accelerating Palvella Therapeutics’ Phase 3 QTORIN trial toward potential approval in rare disease care.
AstraZeneca strikes $50bn U.S. deal to lower drug prices while reshoring manufacturing amid tariff freeze
AstraZeneca inks $50B U.S. deal to cut drug prices and boost onshore manufacturing. See what this means for patients, profits, and pharma’s policy future.
Can AbbVie’s RINVOQ fill the biologics gap for IBD patients unsuitable for TNF therapy?
AbbVie gets FDA approval for broader RINVOQ use in IBD patients beyond TNF blockers. Find out how this impacts stock sentiment and investor expectations.
Amazon’s new pharmacy kiosks let you skip the drugstore line — Here’s how they work inside One Medical clinics
Amazon Pharmacy’s new in-clinic kiosks promise prescriptions in minutes. Find out how this move could redefine US pharmacy models.
How AstraZeneca’s $4.5bn Virginia investment aligns with Trump-era tariffs and U.S. supply chain policy
Find out how AstraZeneca’s $4.5 billion Virginia API plant could reshape global pharma supply chains and investor sentiment in 2025.
Can Bristol Myers Squibb’s $1.5bn Orbital deal make in-vivo CAR-T the next big breakthrough in autoimmune care?
Bristol Myers Squibb’s $1.5 B Orbital buyout bets on in-vivo CAR-T and RNA delivery to reshape autoimmune care. Find out what it means for BMY investors.
Can AstraZeneca’s collaboration with Turbine speed up ADC drug discovery through AI simulation?
AstraZeneca joins hands with AI biotech Turbine to revolutionize antibody-drug conjugate discovery using virtual disease models and lab-in-the-loop design.
Teva’s new bipolar breakthrough: FDA clears UZEDY as the first monthly long-acting risperidone
Teva’s UZEDY long-acting injectable gains FDA approval for bipolar I maintenance, reshaping psychiatric treatment and investor sentiment.
UZEDY wins FDA nod for Bipolar I maintenance therapy, boosting Teva and Medincell’s psychiatric drug portfolio
FDA expands UZEDY approval to Bipolar I maintenance therapy — explore how Teva and Medincell’s long-acting risperidone strategy is reshaping psychiatric care.